Searchable abstracts of presentations at key conferences in endocrinology

ea0019p281 | Reproduction | SFEBES2009

Effect of rimonabant and metformin on GIP and GLP-1 in obese women with polycystic ovary syndrome

Sathypalan Thozhukat , Cho LiWei , Kilpatrick Eric S , Le Roux Carel W , Coady Anne-Marie , Atkin Stephen L

Objective: Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with PCOS compared to metformin. Metformin has also been shown to maintain the weight loss and enhance the metabolic and biochemical parameters achieved by treatment with rimonabant. We have determined the effect of rimonabant on the incretin hormones in patients with PCOS.Design: A randomized open labelled parallel study of metformin...

ea0021p151 | Diabetes and metabolism | SFEBES2009

Effect of rimonabant and metformin on oxidative stress in obese patients with polycystic ovary syndrome (PCOS)

Aye Myint M , Shepherd John , Cho Liwei , Ng J M , Marie Coady Anne , Kilpatrick Eric S , Atkin Stephen L , Sathyapalan Thozhukat

Background: Insulin resistance and obesity are characteristic features of PCOS. Oxidative stress leads to the formation of lipid peroxidation products in the skeletal muscles and has the potential to interfere with insulin signaling and thereby contribute to insulin resistance. Malondialdehyde (MDA) is a lipid peroxidation end product and is widely used as a marker of oxidative stress.Rimonabant has been shown to reduce weight and insulin resistance in o...